Business Description
DanCann Pharma AS
ISIN : DK0061410487
Compare
Compare
Traded in other countries / regions
DANCAN.SwedenDAN.GermanyDCPXF.USA IPO Date
2024-05-10Description
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.34 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.62 | |||||
| Debt-to-EBITDA | -0.47 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -9.3 | |||||
| Beneish M-Score | -17.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 54.6 | |||||
| 3-Year EPS without NRI Growth Rate | 34.7 | |||||
| 3-Year FCF Growth Rate | 70.4 | |||||
| 3-Year Book Growth Rate | -79.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.21 | |||||
| 9-Day RSI | 58 | |||||
| 14-Day RSI | 57.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.4 | |||||
| Quick Ratio | 0.4 | |||||
| Cash Ratio | 0.25 | |||||
| Days Inventory | 7.68 | |||||
| Days Sales Outstanding | 72.62 | |||||
| Days Payable | 54.79 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -187.7 | |||||
| Shareholder Yield % | 7.74 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -50.88 | |||||
| Operating Margin % | -249.07 | |||||
| Net Margin % | -975.22 | |||||
| FCF Margin % | -337.12 | |||||
| ROE % | -126.05 | |||||
| ROA % | -106.55 | |||||
| ROIC % | -27.67 | |||||
| ROC (Joel Greenblatt) % | -729.74 | |||||
| ROCE % | -119.98 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.59 | |||||
| PB Ratio | 1.93 | |||||
| EV-to-EBIT | -0.52 | |||||
| EV-to-EBITDA | -2.44 | |||||
| EV-to-Revenue | 4.79 | |||||
| EV-to-FCF | -1.16 | |||||
| Earnings Yield (Greenblatt) % | -194.92 | |||||
| FCF Yield % | -80.65 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
DanCann Pharma AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.862 | ||
| EPS (TTM) (€) | -0.019 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 57.5 | ||
| 14-Day ATR (€) | 0.001144 | ||
| 20-Day SMA (€) | 0.00342 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 0.001534 - 0.01 | ||
| Shares Outstanding (Mil) | 580.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
DanCann Pharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
DanCann Pharma AS Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
DanCann Pharma AS Frequently Asked Questions
What is DanCann Pharma AS(STU:DAN)'s stock price today?
The current price of STU:DAN is €0.01. The 52 week high of STU:DAN is €0.01 and 52 week low is €0.00.
When is next earnings date of DanCann Pharma AS(STU:DAN)?
The next earnings date of DanCann Pharma AS(STU:DAN) is 2024-08-30.
Does DanCann Pharma AS(STU:DAN) pay dividends? If so, how much?
DanCann Pharma AS(STU:DAN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers